Bank of Montreal Can maintained its stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,068 shares of the biopharmaceutical company’s stock at the end of the 2nd quarter. Bank of Montreal Can’s holdings in Agios Pharmaceuticals were worth $106,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently modified their holdings of the company. Blue Sky Asset Management LLC bought a new position in Agios Pharmaceuticals in the 1st quarter valued at approximately $129,000. Russell Investments Group Ltd. lifted its position in Agios Pharmaceuticals by 163.9% in the 1st quarter. Russell Investments Group Ltd. now owns 2,549 shares of the biopharmaceutical company’s stock valued at $149,000 after acquiring an additional 1,583 shares in the last quarter. Soros Fund Management LLC bought a new position in Agios Pharmaceuticals in the 1st quarter valued at approximately $228,000. Janney Montgomery Scott LLC bought a new position in Agios Pharmaceuticals in the 1st quarter valued at approximately $257,000. Finally, BlueCrest Capital Management Ltd bought a new position in Agios Pharmaceuticals in the 1st quarter valued at approximately $314,000. 94.30% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Agios Pharmaceuticals, Inc. (AGIO) traded up 1.38% during midday trading on Tuesday, reaching $66.00. The company’s stock had a trading volume of 147,667 shares. The stock has a 50-day moving average of $59.16 and a 200 day moving average of $53.96. The firm’s market capitalization is $3.19 billion. Agios Pharmaceuticals, Inc. has a 12-month low of $39.24 and a 12-month high of $67.74.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.57) by ($0.21). The firm had revenue of $11.30 million during the quarter, compared to analyst estimates of $10.68 million. Agios Pharmaceuticals had a negative return on equity of 68.15% and a negative net margin of 502.12%. The company’s revenue was up 62.1% on a year-over-year basis. During the same quarter last year, the company posted ($1.47) EPS. Equities research analysts predict that Agios Pharmaceuticals, Inc. will post ($7.07) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/12/bank-of-montreal-can-continues-to-hold-stake-in-agios-pharmaceuticals-inc-agio.html.

AGIO has been the topic of several analyst reports. Canaccord Genuity set a $90.00 price objective on Agios Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, August 8th. SunTrust Banks, Inc. reissued a “buy” rating and set a $80.00 price target (up from $68.00) on shares of Agios Pharmaceuticals in a report on Tuesday, August 8th. Oppenheimer Holdings, Inc. set a $75.00 price target on Agios Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, June 1st. Cann reissued a “buy” rating and set a $75.00 price target on shares of Agios Pharmaceuticals in a report on Sunday, June 11th. Finally, BidaskClub raised Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, July 13th. Four analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $74.75.

In other Agios Pharmaceuticals news, CEO David P. Schenkein sold 27,000 shares of the company’s stock in a transaction dated Wednesday, August 2nd. The shares were sold at an average price of $59.95, for a total value of $1,618,650.00. Following the completion of the transaction, the chief executive officer now owns 3,000 shares in the company, valued at $179,850. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO David P. Schenkein sold 3,000 shares of the company’s stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $51.18, for a total transaction of $153,540.00. Following the completion of the transaction, the chief executive officer now owns 3,000 shares of the company’s stock, valued at approximately $153,540. The disclosure for this sale can be found here. In the last quarter, insiders sold 86,230 shares of company stock valued at $5,044,882. Insiders own 10.55% of the company’s stock.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO).

Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Stock Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.